Heron Therapeutics
HRTX
200 hedge funds and large institutions have $1.07B invested in Heron Therapeutics in 2021 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 66 increasing their positions, 57 reducing their positions, and 26 closing their positions.
23% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 26
21% more call options, than puts
Call options by funds: $12.5M | Put options by funds: $10.4M
16% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 57
8.95% more ownership
Funds ownership: 106.46% → 115.41% (+9%)
2% more funds holding
Funds holding: 197 → 200 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less capital invested
Capital invested by funds: $1.16B → $1.07B (-$87.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$16.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$15.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$12.3M |
| 4 |
Millennium Management
New York
|
+$10.3M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.01M |
| 3 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
-$7.94M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.24M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$4.13M |
HRTX Hedge Fund Activity: Q4 2021 in Review
200 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2021, worth a combined $1.07B — down 7.5% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new HRTX positions and 26 closed out — a net gain of 6 holders — while 66 added to existing stakes and 57 trimmed.
The largest buyer was UBS O'Connor, adding an estimated $16.8M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $17.1M sold.
- 200 institutional investors held Heron Therapeutics (HRTX) as of Q4 2021, up from 197 in Q3 2021.
- Funds reported $1.07B of Heron Therapeutics stock for Q4 2021, down 7.5% quarter-over-quarter.
- 32 funds opened new Heron Therapeutics positions in Q4 2021 and 26 closed out, a net change of +6 holders.
- The largest Heron Therapeutics buyer in Q4 2021 was UBS O'Connor, an estimated $16.8M added.
- The largest Heron Therapeutics seller in Q4 2021 was Point72 Asset Management, an estimated $17.1M sold.
Based on aggregated 13F filings for Q4 2021.